AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.590
-0.010 (-1.67%)
At close: Dec 27, 2024, 4:00 PM
0.600
+0.010 (1.69%)
After-hours: Dec 27, 2024, 7:50 PM EST
Company Description
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.
The company is based in Irvine, California.
AEON Biopharma, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Marc Forth |
Contact Details
Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States | |
| Phone | (949) 354-6499 |
| Website | aeonbiopharma.com |
Stock Details
| Ticker Symbol | AEON |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001837607 |
| CUSIP Number | 00775E102 |
| ISIN Number | US00791X1000 |
| Employer ID | 85-3940478 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc Forth | Chief Executive Officer |
| Marc Forth | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 424B3 | Prospectus |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 7, 2024 | 8-K | Current Report |
| Aug 21, 2024 | EFFECT | Notice of Effectiveness |
| Aug 21, 2024 | 424B5 | Filing |
| Aug 19, 2024 | UPLOAD | Filing |
| Aug 15, 2024 | S-3 | Registration statement under Securities Act of 1933 |